Screener
Agios Pharmaceuticals AGIO Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026.
- Filed
- Apr 29, 2026, 9:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001439222-26-000073
| (In thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Financing activities | ||
| Net proceeds from stock option exercises and employee stock purchase plan | 2,078 | 1,619 |
| Net cash provided by financing activities | 2,078 | 1,619 |
| Net change in cash and cash equivalents | 24,470 | 2,717 |
| Cash and cash equivalents at beginning of the period | 89,130 | 76,247 |
| Cash and cash equivalents at end of the period | $113,600 | $78,964 |
| Supplemental disclosure of non-cash investing and financing transactions | ||
| Additions to property and equipment in accounts payable | $668 | $221 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's net change in cash?
- Agios Pharmaceuticals (AGIO) reported net change in cash of $24.47M in Q1 2026.
- How has Agios Pharmaceuticals's net change in cash changed year-over-year?
- Agios Pharmaceuticals's net change in cash increased by 800.6% year-over-year, from $2.72M to $24.47M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Agios Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude